Biogen EPS - Earnings per Share 2010-2022 | BIIB

Biogen annual and quarterly earnings per share history from 2010 to 2022. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Biogen EPS for the quarter ending March 31, 2022 was $2.06, a 23.42% decline year-over-year.
  • Biogen EPS for the twelve months ending March 31, 2022 was $9.77, a 49.67% decline year-over-year.
  • Biogen 2021 annual EPS was $10.4, a 58.06% decline from 2020.
  • Biogen 2020 annual EPS was $24.8, a 21.07% decline from 2019.
  • Biogen 2019 annual EPS was $31.42, a 45.6% increase from 2018.
Biogen Annual EPS
2021 $10.40
2020 $24.80
2019 $31.42
2018 $21.58
2017 $11.92
2016 $16.93
2015 $15.34
2014 $12.37
2013 $7.81
2012 $5.76
2011 $5.04
2010 $3.94
2009 $3.35
Biogen Quarterly EPS
2022-03-31 $2.06
2021-12-31 $2.50
2021-09-30 $2.22
2021-06-30 $2.99
2021-03-31 $2.69
2020-12-31 $2.67
2020-09-30 $4.46
2020-06-30 $9.59
2020-03-31 $8.08
2019-12-31 $8.03
2019-09-30 $8.39
2019-06-30 $7.85
2019-03-31 $7.15
2018-12-31 $4.71
2018-09-30 $7.15
2018-06-30 $4.18
2018-03-31 $5.54
2017-12-31 $-1.40
2017-09-30 $5.79
2017-06-30 $4.07
2017-03-31 $3.46
2016-12-31 $3.00
2016-09-30 $4.71
2016-06-30 $4.79
2016-03-31 $4.43
2015-12-31 $3.77
2015-09-30 $4.15
2015-06-30 $3.93
2015-03-31 $3.49
2014-12-31 $3.72
2014-09-30 $3.62
2014-06-30 $3.01
2014-03-31 $2.02
2013-12-31 $1.91
2013-09-30 $2.05
2013-06-30 $2.06
2013-03-31 $1.79
2012-12-31 $1.23
2012-09-30 $1.67
2012-06-30 $1.61
2012-03-31 $1.25
2011-12-31 $1.23
2011-09-30 $1.43
2011-06-30 $1.18
2011-03-31 $1.20
2010-12-31 $0.97
2010-09-30 $1.05
2010-06-30 $1.12
2010-03-31 $0.80
2009-12-31 $1.07
2009-09-30 $0.95
2009-06-30 $0.49
2009-03-31 $0.84
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $29.160B $10.982B
Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.383B 9.82
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.475B 16.53
Biohaven Pharmaceutical Holding (BHVN) United States $9.944B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.681B 0.00
Emergent Biosolutions (EBS) United States $1.444B 6.18
Arcus Biosciences (RCUS) United States $1.389B 35.22
Myovant Sciences (MYOV) United Kingdom $0.879B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.509B 0.00
Gelesis Holdings (GLS) United States $0.362B 0.00
Zymeworks (ZYME) Canada $0.321B 0.00
Ambrx Biopharma (AMAM) United States $0.159B 0.00
Enzo Biochem (ENZ) United States $0.114B 23.50
SQZ Biotechnologies (SQZ) United States $0.093B 0.00